CARB-X is the world’s largest-public-private partnership devoted to early development antibacterial R&D. CARB-X has announced the opening of its 2018 funding cycle to support the early development of antibiotics, vaccines, diagnostics, devices and other life-saving products to respond to the threat of drug-resistant bacterial.
Please join NCBiotech and RTI International as we host the Executive Director of CARB-X, Kevin Outterson, for an informational session about CARB-X and their newest funding cycle. Kevin will provide an overview of the CARB-X initiative and leave plenty of time to get all questions answered. No registration is needed to attend.